Hims & Hers Health (NYSE:HIMS) Sees Unusually-High Trading Volume – Should You Buy?

Hims & Hers Health, Inc. (NYSE:HIMS) shares saw unusually-strong trading volume on Friday . Approximately 5,570,696 shares traded hands during trading, a decline of 38% from the previous session’s volume of 8,949,964 shares.The stock last traded at $25.99 and had previously closed at $27.94.

Analyst Ratings Changes

Several research firms recently commented on HIMS. BTIG Research began coverage on shares of Hims & Hers Health in a research note on Tuesday, January 7th. They set a “buy” rating and a $35.00 target price for the company. Canaccord Genuity Group increased their target price on shares of Hims & Hers Health from $28.00 to $38.00 and gave the stock a “buy” rating in a research report on Monday, December 2nd. Needham & Company LLC boosted their target price on shares of Hims & Hers Health from $28.00 to $31.00 and gave the stock a “buy” rating in a research report on Monday, January 6th. Morgan Stanley started coverage on Hims & Hers Health in a research note on Tuesday, December 17th. They issued an “overweight” rating and a $42.00 price objective on the stock. Finally, Citigroup cut Hims & Hers Health from a “neutral” rating to a “sell” rating and boosted their price objective for the stock from $24.00 to $25.00 in a research report on Friday, January 10th. Two equities research analysts have rated the stock with a sell rating, seven have assigned a hold rating and eight have issued a buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $25.13.

Hims & Hers Health Price Performance

The firm has a market cap of $5.97 billion, a P/E ratio of 62.09 and a beta of 1.31. The company has a fifty day moving average of $27.60 and a 200-day moving average of $21.80.

Hims & Hers Health (NYSE:HIMS) last released its quarterly earnings data on Monday, November 4th. The company reported $0.32 EPS for the quarter, beating the consensus estimate of $0.06 by $0.26. The business had revenue of $401.56 million for the quarter, compared to the consensus estimate of $382.20 million. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. The company’s revenue was up 77.1% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.04) earnings per share. On average, sell-side analysts expect that Hims & Hers Health, Inc. will post 0.29 EPS for the current fiscal year.

Insider Activity at Hims & Hers Health

In other Hims & Hers Health news, insider Soleil Boughton sold 2,339 shares of the business’s stock in a transaction dated Tuesday, October 29th. The stock was sold at an average price of $23.16, for a total transaction of $54,171.24. Following the completion of the sale, the insider now directly owns 169,935 shares in the company, valued at $3,935,694.60. The trade was a 1.36 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Michael Chi sold 2,054 shares of the company’s stock in a transaction dated Monday, December 2nd. The stock was sold at an average price of $33.56, for a total value of $68,932.24. Following the completion of the sale, the insider now owns 184,947 shares of the company’s stock, valued at approximately $6,206,821.32. The trade was a 1.10 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 1,080,208 shares of company stock valued at $29,106,823. Insiders own 17.71% of the company’s stock.

Institutional Trading of Hims & Hers Health

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Main Management ETF Advisors LLC purchased a new stake in Hims & Hers Health in the 3rd quarter worth about $672,000. Robeco Institutional Asset Management B.V. purchased a new stake in shares of Hims & Hers Health during the 3rd quarter worth $604,000. Carnegie Investment Counsel purchased a new position in shares of Hims & Hers Health in the 3rd quarter worth approximately $5,531,000. Royce & Associates LP increased its position in shares of Hims & Hers Health by 17.0% during the third quarter. Royce & Associates LP now owns 341,000 shares of the company’s stock worth $6,281,000 after purchasing an additional 49,500 shares in the last quarter. Finally, Versor Investments LP purchased a new stake in Hims & Hers Health in the third quarter valued at about $634,000. 63.52% of the stock is currently owned by institutional investors.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.